It should be noted that the proportion of HER-2-positive ductal carcinomas in situ (DCIS) is significantly higher than that of more advanced cases (Muggerud et al., 2010; Zhang et al., 2012). The gene discussed is ERBB2; the disease is ductal breast carcinoma in situ.